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Abstract: 1 
Kinases have emerged as one of the most intensively pursued targets in current pharmacological 2 
research, especially for cancer, due to their critical roles in cellular signaling. To date, the USA 3 
Food and Drug Administration (FDA) has approved twenty-eight small molecule kinase inhibitors, 4 
half of which were approved in the past three years. While the clinical data of these approved 5 
molecules are widely presented and structure-activity relationship (SAR) has been reported for 6 
individual molecules, an updated review that analyzes all approved molecules and summarizes 7 
current achievements and trends in the field has yet to be found.  Herein we present all approved 8 
small molecule kinase inhibitors with an emphasis on binding mechanism and structural features, 9 
summarize current challenges, and discuss future directions in this field. 10 
 11 
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Kinase inhibitors: A burgeoning field 1 
The past one and half decades witnessed an unparalleled success in the development of 2 
therapeutically useful kinase inhibitors, powered by tremendous progress in both academic and 3 
industrial settings.  The milestone approval of the first kinase inhibitor, imatinib, in 2001 by FDA, 4 
was followed by a slow, yet steady approval of kinase inhibitors in the first ten years of this 5 
century with almost one new approval per year on average. Concurrently, our understanding of 6 
kinase signaling networks and disease pathology steadily grew, culminating in the approval of 7 
fifteen new small molecule kinase inhibitors from January 2012 to February 2015 - an unparalleled 8 
achievement in the history of pharmaceutical research.  As of March 2015, a total of twenty-eight 9 
small molecule kinase inhibitors have been approved along with a large number of other 10 
compounds currently being evaluated in clinical and preclinical trials. In addition, more than one 11 
million publications on kinases have been released, more than five thousand crystal structures of 12 
kinases with or without small molecules have been solved, inhibition assays have been developed 13 
for more than four-fifths of the human kinome, and small molecule kinase inhibitors have been 14 
identified for about one-fifth of the human kinome. All these facts reflect the surging interest in 15 
this field. Thus, it is now safe to state that the development of small molecule kinase inhibitors has 16 
emerged as one of the most extensively pursued areas of drug discovery. In spite the abundance 17 
of data, common binding modes and structural features of approved small molecule kinase 18 
inhibitors are rarely reported in a systematic way that is easily accessible. Instead, information on 19 
individual inhibitors and their analogues appears scattered and fragmented. In this review, we 20 
provide a comprehensive overview and discuss the function mechanism and structural binding 21 
features of approved small molecule kinase inhibitors based on co-crystal structures. With the 22 
notion that fifteen kinase inhibitors were approved by FDA in the short period from 2012 to 23 
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February 2015, emphasis will be put on those small molecules, for which few SAR discussions have 1 
been presented. The intention of this review is to compile structural and binding information 2 
useful for the discovery of new kinase inhibitors, summarize current limitations and challenges, 3 
and propose future directions in the field in light of the most successful design-to-approval 4 
examples. 5 
Kinases  6 
Kinases catalyze the transfer of the γ-phosphate group of ATP onto a substrate, mediate most 7 
signal transductions [1], and regulate various cellular activities, including proliferation, survival, 8 
apoptosis, metabolism, transcription, differentiation, and a wide array of other cellular processes 9 
[2]. Accumulating pharmacological and pathological evidence have revealed that kinases are 10 
promising drug targets for the treatment of numerous diseases [3], such as cancers [4-6], 11 
inflammatory diseases [7, 8], central nervous system (CNS) disorders [9], cardiovascular diseases 12 
[10], and complications of diabetes [11].  13 
    Pioneering studies on the characterization of the phosphorylase kinase in the 1950s [12-14], and 14 
the identification of the first kinase signaling cascade involving protein kinase A (PKA) in 1968 [15], 15 
constituted the first few pieces of the jigsaw puzzle of kinase cascades. The “decade of protein 16 
kinase cascades” in 1990s witnessed the unfolding of the mitogen-activated protein 17 
kinases/extracellular signal-regulated kinases (MARK/ERK, also known as Ras-Raf-MEK-ERK) 18 
pathway, the Janus kinases (JAK) pathway, and the phosphoinositide 3-kinase (PI3K) pathway [16, 19 
17]. So far, 518 human kinases and more than 900 genes encoding proteins with kinase activity 20 
have been confirmed [18, 19]. Albeit accounting for only about 5% of the total number of protein-21 
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coding genes [20], kinases comprise one of the largest classes of proteins encoded by the human 1 
genome.  2 
Kinase inhibitors 3 
Although diverse in primary amino acid sequence, the human kinases share a great degree of 4 
similarity in their three-dimensional structures, especially in their catalytically active kinase 5 
domain where the ATP binding pocket is located: a β-sheet containing N-terminal lobe (N-lobe), α-6 
helix dominated C-terminal lobe (C-lobe), and a connecting hinge region [21]. ATP binds in the 7 
cleft formed between the N- and C-lobes and most kinase inhibitors perturbs binding through 8 
interactions with this region. A flexible activation loop starting with a conserved amino acid 9 
sequence Asp-Phe-Gly (DFG) controls access to the active site [22] (Figure 1A). Categorized by 10 
binding modes, kinase inhibitors can be grouped into two classes: irreversible and reversible 11 
inhibitors. The former tend to covalently bind with a reactive nucleophilic cysteine residue 12 
proximal to the ATP binding site, resulting in the blockage of the ATP site and irreversible 13 
inhibition. The latter can be further classified into four main types based on the conformation of 14 
binding pocket and the DFG motif [23, 24] (Figure 1B). Type I inhibitors are ATP competitive 15 
inhibitors that bind to the active forms of kinases with the aspartate residue of the DFG motif 16 
facing into the active site of the kinase. Type II inhibitors bind to the inactive forms of kinase with 17 
the aspartate residue of the DFG motif protruding outwards from the ATP binding site of the 18 
kinase. Many type II inhibitors exploit specific pockets accessible in a region adjacent to the ATP 19 
binding site due to the rotation of the DFG motif.  In the type III binding mode, inhibitors bind 20 
exclusively in an allosteric pocket adjacent to ATP without making any interaction with the ATP 21 
binding pocket. Type IV inhibitors bind to an allosteric site remote from the ATP binding pocket 22 
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[25]. Besides, some kinase inhibitors, such as bisubstrate and bivalent inhibitors (Type V) [26], 1 
exhibit more than one of the above-mentioned binding modes.  2 
Small molecule kinase inhibitors are useful reagents to investigate and elucidate kinase 3 
functions in various cellular activities [5]. The dominant dogma that the kinase domain was too 4 
conserved to enable the selective inhibition by small molecules was challenged in the late 1980s 5 
when the first examples of selective kinase inhibitors against the epidermal growth factor receptor 6 
(EGFR) were reported [27, 28]. Since then, a large number of kinase inhibitors of various structural 7 
features and inhibition profiles have been identified aided by the deepening understanding of 8 
structural biology [3], especially the kinase/inhibitor binding complex elucidated by high resolution 9 
X-ray crystallography [29, 30].   10 
    Among the 28 clinically approved kinase inhibitors, most are tyrosine kinase inhibitors [31], few 11 
are serine/threonine kinase inhibitors, and one, idelalisib, is a lipid kinase inhibitor that was 12 
approved in Jul., 2014 (Figure 2). Judged by different binding modes, 26 are reversible inhibitors, 13 
and the remaining two, afatinib and ibrutinib, are irreversible inhibitors. Despite several promising 14 
allosteric kinase inhibitors being currently in clinical trials at different stages, trametinib is the only 15 
type III inhibitor approved so far. In this review, approved small molecule kinase inhibitors are 16 
discussed and grouped into different classes based on their binding modes and targets. 17 
Approved tyrosine kinase inhibitors 18 
Reversible non-receptor tyrosine kinase (NRTK) inhibitors  19 
BCR-Abl was the first kinase for which a small molecule inhibitor was successfully approved [32]. 20 
On another note, being the first approved kinase inhibitor and a revolutionary success for the 21 
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treatment of chronic myeloid leukemia (CML) [17], imatinib has been the subject of various SAR 1 
studies to guide the design of next-generation inhibitors and provide a deeper understanding of 2 
the inhibition mechanism. Considerable efforts seek to develop inhibitors based on structural 3 
features derived from imatinib and its binding mode with BCR-Abl [33, 34]. Five BCR-Abl inhibitors 4 
have been approved so far: imatinib (Gleevec®, Novartis), dasatinib (Sprycel®, Bristol-Myers-5 
Squibbs), nilotinib (Tasigna®, Novartis), Bosutinib (Bosulif®, Wyeth), and Ponatinib (Iclusig®, Ariad 6 
Pharm.).  7 
Imatinib, nilotinib, and ponatinib bind with inactive BCR-Abl with the DFG-motif adopting an 8 
“out” conformation, utilizing three binding pockets (Figure 3). The pyridine-pyrimidine moiety of 9 
imatinib forms a conserved hydrogen bond with hinge residue Met318. The tolyl group occupies a 10 
hydrophobic pocket, and the amino group of the tolylaminopyrimidine moiety forms a hydrogen 11 
bond with the gate-keeper residue Thr315. The terminal piperazinylphenyl group binds inside an 12 
allosteric pocket, formed due to the flipped conformation of the DFG motif, where the piperazinyl 13 
amine forms bidentate ionic interactions with His361 and Ile360. Besides, hydrogen bonds are 14 
formed between the amide connecting link and Glu286, Asp 381 [35] (Figure 3A and 3B). In spite 15 
of high efficacy and limited toxicity in comparison with traditional chemotherapy drugs, point 16 
mutations in the kinases domain of BCR-Abl led to the development of drug resistance against 17 
imatinib [36, 37]. Thus, nilotinib was developed as a second-line therapy for CML that is imatinib-18 
resistant due to point mutations on BCR-Abl, including E255V, M351T, and F486S. Nilotinib shares 19 
the same pyridine-pyrimidine-aminotolyl moiety with imatinib, the difference being the long chain 20 
binding within the allosteric pocket. The imidazole-phenyl moiety and the attached 21 
trifluoromethyl group make it possible for nilotinib to bind deeper and tighter within the allosteric 22 
pocket (Figure 3C and 3D). Nilotinib is potent against most mutations but not the common 23 
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gatekeeper mutation T315I which blocks the binding into the allosteric pocket due to mutation of 1 
the small threonine residue to a bulky isoleucine residue. In this context, ponatinib was developed 2 
as a new BCR-Abl inhibitor that exhibits potent T315I inhibitory activity. Instead of having a 3 
pyrimidineamino linker interacting with the gatekeeper residue Thr315, a slim alkyne linker that 4 
overcomes steric hindrance due to mutation of the gate-keeper residue was incorporated in 5 
ponatinib. Besides, ponatinib bears the piperizinylphenyl group of imatinib and the trifluoromethyl 6 
group of nilotinib, resulting in a more compact interaction with the allosteric pocket (Figure 3E and 7 
3F). 8 
Dasatinib and Bosutinib are the two approved inhibitors that bind with the active conformation 9 
of BCR-Abl with the activation loop fully extended for substrate binding. As for dasatinib (Figure 10 
4A), the nitrogen of the thiazole core and the attached amino group form hydrogen bonds with 11 
hinge residue Met318. The long hydroxyethylpiperazinyl tail is exposed to the solvent region. The 12 
terminal toluidine group points towards a hydrophobic pocket close to the gatekeeper residue 13 
Thr315, which interacts with the connecting amide link through a hydrogen bond (Figure 4B and 14 
4C). Thus, T315I mutation related drug resistance also occurs in patients treated with dasatinib. In 15 
contrast to the other four approved BCR-Abl molecules, bosutinib bears an anilinequinoline core 16 
that is similar to the anilinequinazoline core of some EGFR inhibitors (Figure 4D). A hinge hydrogen 17 
bond is formed between the quinoline nitrogen and the backbone amide of Met 318.  The 18 
substituted aniline group occupies the hydrophobic pocket adjacent to Thr315. The nitrile group 19 
extends into another Thr315-adjacent pocket, which may host water molecules to form conserved 20 
water-mediated hydrogen bond interactions with small molecule inhibitors to contribute to kinase 21 
selectivity [38]. Due to the propensity of BCR-Abl to adopt a certain conformation at low pH values 22 
needed for crystallization, the DFG-motif of the bosutinib-Abl complex exhibits a different 23 
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conformation from that of dasatinib-Abl complex (Figure 4E and 4F). While a bosutinib-Src 1 
complex with the DFG-motif adopts the same conformation as shown in the dasatinib-Abl complex 2 
has been reported recently [38]. 3 
    Janus kinases (JAKs) are a family of intracellular NRTKs that are required for multiple signaling 4 
pathways initiated by cytokines and growth factor receptors to phosphorylate Signal Transducers 5 
and Activators of Transcription (STAT) proteins [39, 40]. Four isomers, JAK1, JAK2, JAK3 and 6 
Tyrosine kinase 2 (TYK2) have been identified as JAK family kinases. JAK3 is exclusively expressed 7 
in cells of the lymphoid lineage and plays important roles in the immune system [41], while the 8 
other three isoforms are ubiquitously expressed and regulate a range of physiological functions 9 
[42]. Although small molecule kinase inhibitors against JAKs are potential agents for the treatment 10 
of autoimmune and neoplastic disorders [43], the development of isoform-selective JAK inhibitor 11 
is challenging due to the high sequence similarity among the four JAK kinases [7]. 12 
    Ruxolitinib (Jakafi®, Incyte Corp.) was the first approved JAK inhibitor (Figure 5A). It inhibits both 13 
JAK1 and JAK2 and is used for the treatment of myeloproliferative disorders, such as myelofibrosis. 14 
Tofacitinib (Xeljanz®, Pfizer) was approved by FDA as a JAK3 selective inhibitor in 2012 for the 15 
treatment of rheumatoid arthritis (Figure 5B). However, the efficacy of tofacitinib has been 16 
hindered by side effects, such as anemia and neutrophenia, probably due to undesirable pan-JAK 17 
inhibition, thus it was not approved by European regulatory agencies. Both molecules bear a 18 
pyrrolo[2,3-d]pyrimidine scaffold, and whereas no co-crystal structure of ruxolitinib with JAK 19 
kinase has been published yet, crystal complexes of tofacitinib with JAK1, JAK2, and JAK3 are 20 
readily available [44, 45]. Tofacitinib binds within the ATP pocket of JAKs. The pyrrolo[2,3-21 
d]pyrimidine scaffold forms two hydrogen bonds with hinge residues Leu905 and Glu903 in JAK3 22 
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(Leu932 and Glu930 in JAK2). The terminal cyanoacetyl handle extends into a cleft underneath the 1 
P-loop in the N-lobe. The methyl group of the piperidine ring occupies a small hydrophobic pocket 2 
in the C-lobe (Figure 5C and 5D). Compounds with better selectivity towards JAK3 and reduced 3 
side effects are currently being investigated as the next generation JAK inhibitors [46, 47]. 4 
Reversible receptor tyrosine kinase (RTK) inhibitors  5 
ErbB, named for their homology to the erythroblastoma viral gene product v-ErbB, is a family of 6 
RTKs that includes four members, ErbB1/epidermal growth factor receptor (EGFR), ErbB2/human 7 
epidermal growth factor receptor 2 (Her2), ErbB3/Her3, and ErbB4/Her4 [48]. The ErbB cascade is 8 
one of the most extensively studied signaling transduction pathways [49, 50], and the ErbB 9 
inhibitors gefitinib (Iressa®, AstraZeneca), erlotinib (Tarceva®, OSI Pharm.), lapatinib (Tykerb®, 10 
GlaxoSmithKline), vandetanib (Caprelsa®, AstraZeneca), and afatinib (Gilotrif®, Boehringer 11 
Ingelheim) constitute one of the largest groups of approved small molecule kinase inhibitors. All 12 
five inhibitors bear a common quinazoline scaffold occupying the ATP adenine binding pocket, a 4-13 
amino substituent binding in a hydrophobic pocket close to the kinase hinge, and a long chain in 14 
the 6- and/or 7-position extending towards solvent to increase the overall solubility of the 15 
molecule. In contrast to the other four reversible inhibitors, afatinib bears an enone moiety in the 16 
long solubilizing chain, enabling it to form a covalent bond. Thus, afatinib will be discussed 17 
together with ibrutinib in the section for covalent inhibitors.     18 
A complex of wide type EGFR with gefitinib was first reported in 2007 [51] (Figure 6A and 6B). 19 
Structures of EGFR kinases with mutations at L858R or T790M have also been solved by several 20 
different groups. Extensive efforts to crystalize drug-resistant double mutant L858R+T790M EGFR 21 
failed to give diffraction-quality crystals, until a structure of EGFR with L858R+T790M+V948R 22 
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mutations was recently co-crystalized with gefitinib [52] (Figure 6C). In contrast to the wild type 1 
EGFR conformation that showed an active state with Leu858 buried in the kinase N-lobe, this 2 
mutant EGFR structure adopted an inactive-like state where Arg858 residue is exposed to the 3 
solvent front. Although gefitinib, erlotinib and vandetanib are the few inhibitors for which no 4 
experimental evidence regarding inactive state recognition has been collected so far, this gefitinib-5 
mutant EGFR co-crystal structure showed that maybe there is no structural hindrance for these 6 
inhibitors to bind with the inactive form of EGFR. SAR and structural features obtained from these 7 
mutant kinase complexes provide a new dimension for the development of kinase inhibitors that 8 
may better address challenging issues regarding selectivity and drug-resistance. Due to the high 9 
structural similarity, the erlotinib-EGFR complex showed the same binding mode with that of 10 
gefitinib-EGFR complex, albeit with different 6,7-quinazoline substituents exposed in the solvent 11 
region [53] (Figure 6D-6F).  12 
Lapatinib is a dual EGFR and ErbB2 inhibitor. In contrast to the type I binding mode as shown for 13 
erlotinib and gefitinib, lapatinib binds with the inactive conformation of EGFR, utilizing not only 14 
the adenine pocket and the specific hydrophobic pocket, but also an allosteric pocket formed due 15 
to the conformation change of the DFG-motif  [54] (Figure 6G, 6H). Equivalent to its binding with 16 
EGFR, lapatinib binds with the inactive conformation of ErbB4, which shares the same lapatinib-17 
contacting residues with ErbB2 [55] (Figure 6I).  Although it has been assumed that allosteric 18 
modulators like type II inhibitors may achieve higher selectivity in comparison with type I 19 
inhibitors due to the utilization of an allosteric pocket unfolded through the conformational 20 
change[56], some of the currently available allosteric inhibitors are highly nonselective and a 21 
recent binding mode analysis suggested that type II inhibitors do not show an intrinsic selectivity 22 
advantage over type I inhibitors [57].  23 
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Vandetanib is a multiple kinase inhibitor against EGFR, vascular endothelial growth factor 1 
(VEGFR), and RET [58]. Despite the absence of a vandetanib-EGFR complex, a co-crystal structure 2 
of vandetanib with RET of class XIV RTK showed the same type I binding as seen in gefitinib and 3 
erlotinib [58](Figure 6J-6L). 4 
    VEGFRs, comprised of three major isoforms, 1, 2, and 3, are receptors of vascular endothelial 5 
growth factor (VEGF) that is an important signaling protein in vasculogenesis and angiogenesis [59, 6 
60]. Like Bcr-Abl and EGFR, VEGFR is among the earliest and most extensively-studied kinases 7 
targeted by synthetic small molecules for cancer treatment. Seven approved small molecule 8 
inhibitors target VEGFR as their primary target: sorafenib (Nexavar®, Bayer), sunitinib (Sutent®, 9 
Pfizer), pazopanib (Votrient®, GlaxoSmithKline), axitinib (Inlyta®, Pfizer), regorafenib (Stivarga®, 10 
Bayer), nintedanib (Ofev®,Boehringer Ingelheim), and lenvatinib (Lenvima®, Eisai Inc.). 11 
The binding mode of VEGFR with small molecule inhibitors has been the subjects of SAR 12 
discussions in many studies due to the early resolution of corresponding co-crystal structures. 13 
General binding mode and common structural features are shown based on the VEGFR2-14 
complexes that are available for four of the seven approved VEGFR inihibitors [61] (Figure 7A-7H): 15 
the conserved hinge bond is formed between the picolinamide group of sorafenib with Cys919, 16 
the indolinone core of sunitinib with Glu917 and Cys919, the indazole core of axitinib with Glu917 17 
and Cys919, and the indolinone core of nintedanib with Glu917 and Cys919. Except for sunitinib, 18 
the allosteric pocket formed due to the relocation of the DFG group is utilized by the remaining 19 
three molecules: the terminal 4-chloro-3-(trifluoromethyl)phenyl group of sorafenib binds in a 20 
deep hydrophobic allosteric pocket and the urea group lying in an allosteric channel forms 21 
hydrogen bonds with N-lobe residue Glu885 and the activation loop residue Asp 1046, axitinib 22 
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interacts with a small part of the allosteric pocket through its terminal benzamide group, and 1 
nintedanib binds with the allosteric pocket using its terminal methylcarboxy group.  Another 2 
difference among these four compounds is the presence of a solubilizing chain: both sunitinib and 3 
nintedanib have a long terminal chain lying in the solvent region, axitinib’s moderate-length 4 
pyridylvinyl chain extends to the solvent front, while sorafenib is basically buried inside the 5 
binding pocket without direct interaction with the solvent. In the case of nintedanib, ionic 6 
interactions are formed between the N-methylpiperazinyl group and Glu850. Regorafenib only 7 
differs from sorafenib by the presence of a fluorine atom (Figure 7I), thus similar type II binding 8 
with VEGFR2 as for sorafenib is expected. Both sorafenib and regorafenib are multi-target protein 9 
kinase inhibitors. Besides inhibition of VEGFR and B-raf, sorafenib has also been shown to be a 10 
potent low nanomolar inhibitor of p38α through binding with its inactive conformation (3GCS, 2.1 11 
Å) [62]. A predicted type II binding mode of pazopanib with VEGFR2 is depicted (Figure 7J) based 12 
on a VEGFR2-complex with a similar indazolylpyrimidine-2,4-diamine compound that only differs 13 
in the aniline substituent at the 2-position of the pyrimidine-2,4-diamine [63].  Although a co-14 
crystal structure of VEGFR2 with lenvatinib (PDB ID: 3WZD) has been reported in November 2014 15 
[64], for unspecified reasons, it is still not accessible through the PDB database. It was reported 16 
that lenvatinib binds into both the ATP binding site and a neighboring allosteric region of VEGFR2 17 
with the DFG motif adopting an “in” conformation (Figure 7K), making it an inhibitor that 18 
possesses both type I and II binding features [64].  19 
     Anaplastic lymphoma kinase (ALK) is a RTK that shares great sequence similarity to leukocyte 20 
tyrosine kinase (LTK) [65]. Chromosomal rearrangements in ALK have been detected in different 21 
types of human cancer, and together with other oncogenic evidence, ALK has been adopted as 22 
14 
 
another attractive target for cancer treatment with more than 10 molecules currently undergoing 1 
clinical trials [66]. 2 
Crizotinib (Xalkori®, Pfizer) was the first ALK inhibitor approved (Figure 8A), for the treatment of 3 
late stage lung cancer, anaplastic large cell lymphoma, and neuroblastoma. It was also the first 4 
drug specifically targeting NSCLC patients. Besides ALK, crizotinib also acts on ROS proto-oncogene 5 
1 encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene 6 
encoded kinase (MET) of the hepatocyte growth factor receptor (HGFR) class[67, 68]. A co-crystal 7 
structure with ALK showed that crizotinib binds with the ATP-binding pocket in a type I mode. The 8 
aminopyridine core sits at the adenine pocket and makes hydrogen bonds with hinge residues 9 
Glu1197 and Met1199. The methyl group of the benzyloxy moiety binds with a small hydrophobic 10 
pocket under the N-lobe. The 2,6-dichloro substituent of the terminal benzyl handle contributes to 11 
the high potency against c-MET. Overall, crizotinib does not fully utilize the structural features of 12 
the ATP binding pocket of ALK, which partially explained its poor selectivity [68] (Figure 8B, 8C). 13 
Ceritinib (Zykadia®, Novartis) was developed as a second-generation ALK inhibitor for the 14 
treatment of non-small-cell lung carcinoma (NSCLC) with developed resistance to crizotinib due to 15 
rearrangements of the ALK gene[69] (Figure 8D). It has been shown that ceritinib potently 16 
overcomes ALK bearing L1196M, G1269A, I1171T, and S120Y mutations, but not ALK with G1202R 17 
and F1174C mutations [70].  ALK-ceritinib co-crystal structure showed a similar binding mode to 18 
that of ALK-crizotinib complex with the DFG motif adopting the “in” conformation [70]. The 19 
conserved hydrogen bonds were formed between the 2,4-diaminopyrimidine core and hinge 20 
residue Met1199. The isopropylsulfonylphenyl handle binds deeper inside the hydrophobic pocket, 21 
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and the anchor-shaped terminal 2-isopropoxy-3-(piperidin-4-yl)phenyl group lies in the interface 1 
between solvent and the ATP binding pocket. 2 
    MET, or c-MET, is a tyrosine kinase that is the only know receptor of HGF [71, 72]. MET induced 3 
activation of signaling cascade recruits downstream effectors including SRC, PI3K, tyrosine 4 
phosphatase SRC homology 2 domain-containing phosphatase 2 (SHP2), transcription factor signal 5 
transducer, and activator of transcription (STAT-3), regulating proliferation, motility, migration, 6 
and a wide range of other cellular activities [73]. Given its pivotal role in cancer development and 7 
progression, MET has been promoted as a versatile candidate for cancer treatment [74]. Besides a 8 
small group of selective MET inhibitors, most current MET inhibitors target multiple kinases, 9 
including the two approved molecules: above-mentioned crizotinib and the dual MET and VEGFR2 10 
inhibitor cabozantinib (Cometriq®, Exelixis). A recent study showed that cabozantinib overcomes 11 
crizotinib resistance stemming from acquired mutations in ROS1 [75]. 12 
    MET-crizotinib complex showed a type I binding mode similar to that of the ALK-crizotinib 13 
complex with the DFG adopting an “in” conformation [68] (Figure 9A). The hinge hydrogen bonds 14 
involving the aminopyridine core are preserved, while the 3-fluoro-2,6-dichlorobenzyl moiety 15 
binds in a big hydrophilic pocket adjacent to the solvent front (Figure 9B, 9C). In spite of the 16 
absence of a MET co-crystal structure with cabozantinib (Figure 9D), the MET complex with 17 
compound DWF (Figure 9E), a closely related analogue, showed a potent type II binding mode. The 18 
aminopyrimidine core and the connecting fluorophenyl group lie in the adenine pocket and 19 
hydrophobic pocket utilized by crizotinib, respectively. The DFG-out conformation opens a 20 
hydrophobic allosteric pocket that is occupied by the terminal 4-fluorophenyl group. Besides 21 
forming a hydrogen bond with the N-lobe residue Lys1110, the cyclopropane-dicarboxamide link 22 
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binds with an allosteric channel interacting directly with the DFG residue Asp1222 through the 1 
formation of a hydrogen bond. The sulfonylphenyl group extends to the solvent and forms 2 
hydrogen bonds with C-lobe residues Asp1164 and Asn1167 (Figure 9F, 9G).  3 
Approved irreversible protein kinase inhibitors 4 
The EGFR inhibitor afatinib was the first clinically approved irreversible kinase inhibitor, followed 5 
shortly by ibrutinib in November 2013. The approval of these two molecules validates the strategy 6 
of incorporating Michael acceptor functionality in small molecule inhibitors to form a covalent 7 
bond with a cysteine residue in the active site of kinases. This type of irreversible inhibitors is 8 
expected to achieve greater specificity and potency, although concerns have been raised regarding 9 
potential toxicities.  10 
Co-crystal structures of both wide type EGFR-afatinib and mutant T790M EGFR-afatinib showed 11 
a type I binding mode that is in high degree of similarity with other approved reversible EGFR 12 
inhibitors sharing the same anilinoquinazoline core (Figure 10A). A conserved hydrogen bond is 13 
formed between hinge residue Met793 and the quinazoline ring. Electron density indicated that 14 
formation of a covalent C-S bond (1.8 Å) between the enone tail and Cys797 at the edge of the 15 
active site in the C-lobe [76] (Figure 10B, 10C).  16 
Ibrutinib (Imbruvica®, Pharmacyclics Inc.) is a non-receptor tyrosine kinase inhibitor that targets 17 
Bruton’s tyrosine kinase (BTK), which is an essential component of B-cell receptor signaling in 18 
regulating survival and proliferation of chronic lymphocytic leukemia (CLL) cells [77]. It was 19 
approved for the treatment of mantle cell lymphoma in November 2013, and then for CLL in 20 
February 2014 [78]. Global sales of Ibrutinib are expected to reach 9 billion US dollars in 2020 [79]. 21 
A co-crystal structure of BTK with ibrutinib has yet to be reported, but one of BTK with a close 22 
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analogue of ibrutinib, B43, could be used to deduce a general binding mode between BTK and 1 
ibrutinib [80] (Figure 10D, 10E). B43 binds to the ATP site with the activation loop displaying a 2 
“DFG-in” conformation. The 4-amino pyrrolopyrimidine of B43 mimics the adenine ring of ATP, 3 
making several hydrogen bond interactions with the hinge region. The terminal phenyl group is 4 
twisted out of the connecting phenyl ether plane to enter a hydrophobic pocket mainly formed by 5 
the N-lobe residues.  The phenoxyphenyl group forms π-stacking interactions with residues of this 6 
hydrophobic pocket. The cyclopentyl group of B43 extends towards Cys481 of the activation loop 7 
(Figure 10F). In the case of ibrutinib, the cyclopentyl group is replaced with an N-acryloylpiperidine 8 
group that acts as a Michael acceptor in reaction with the vicinal cysteine.  9 
Approved serine/threonine kinase inhibitors                   10 
Serine/threonine kinase B-Raf, one of the three isoforms of the Raf family, has been established as 11 
an attractive anticancer target [81]. Replacement of Val600 with Glu600 within the activation loop 12 
of the kinase domain accounts for 90% of B-Raf mutations [82], resulting in destabilization of the 13 
inactive conformation, elevated activation of the MAPK pathway, and enhanced promotion of cell 14 
survival and proliferation. Efforts in developing small molecule kinase inhibitors lend to the 15 
approved of the first B-Raf inhibitor Vemurafenib (Zelboraf®, Roche) in 2011 for the treatment of 16 
metastatic melanoma and thyroid tumors [81], followed by the approved of Dabrafenib (Tafinlar®, 17 
GlaxoSmithKline) in 2013. Besides, the tyrosine kinase inhibitor sorafenib has also been shown to 18 
inhibit Raf kinases including C-Raf and B-Raf [82].  19 
Vemurafenib (Figure 11A) was developed using a fragment-based drug discovery strategy. The 20 
V600E B-Raf-vemurafenib co-crystal structure showed a type I binding mode. Vemurafenib 21 
occupies the ATP binding site with a DFG-in conformation, enabling the formation of hydrogen 22 
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bond interactions between the sulfonamide moiety and the DFG residues. Hydrogen bonds are 1 
also formed between the pyrrolopyridine core and hinge residue Cys532 and Gln530, mimicking 2 
that of the adenine core of ATP. The terminal 4-chlorophenyl group is exposed to the solvent front. 3 
Besides, an outward shift of the regulatory αC-helix caused by vemurafenib binding to the kinase 4 
was observed [83] (Figure 11B, 11C). Although no co-crystal structure of dabrafenib (Figure 11D) 5 
with B-Raf has been obtained yet, a complex of mutant V600E B-Raf with compound 20 (Figure 6 
11E), a diarylthiazole derivate of dabrafenib, showed an interacting mode that shares features of 7 
type I binding. Compound 20 binds the ATP site with the activation loop adopting a DFG-in 8 
conformation.  Hydrogen bond interactions with the hinge and the DFG residues were preserved 9 
through the acetamidopyridine handle and the sulfonamide moiety, respectively. The 2,5-10 
difluorophenyl moiety extends inside a hydrophobic pocket, or Ras-selective pocket, which is 11 
formed through the outward movement of the αC-helix. The thiazole core occupies the ribose 12 
pocket that is barely utilized by other kinase inhibitors, and the cyclopropylpiperidine tail attached 13 
to the thiazole core extends towards the solvent environment [84] (Figure 11F). A mechanistic 14 
study indicated that the activation loop of B-Raf is held in an inactive state by association with the 15 
P-loop. Mutations of the activation loop or the P-loop disrupt the inactive conformation and 16 
convert B-Raf into its active conformation. Co-crystal structure of tyrosine kinase inhibitor 17 
sorafenib with both wild type and mutant B-Raf showed different binding modes when the Val599 18 
of the activation loop is mutated to Glu599 [82] (Figure 11G-11I). 19 
    Along the MAPK pathway, MEK is another target for which a considerable number of small 20 
molecule inhibitors have been identified [85], including the only approved molecule trametinib 21 
(Mekinist®, GlaxoSmithKline) (Figure 12A). Trametinib was developed based on a high-throughput 22 
screening hit that bears the same pyridopyrimidinetrione core. SAR studies driven by growth 23 
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inhibitory activity against cancer cell lines lead to the discovery of trametinib [86], whose target 1 
was then confirmed as MEK1 and MEK2 guided by the structural features of known MEK inhibitors. 2 
The co-crystal structure of MEK1 with an analogue of trametinib, TAK-733 (Figure 12B), showed a 3 
type III binding mode. The pyridopyrimidinedione core lies in an allosteric pocket adjacent to the 4 
ATP binding pocket with the pyridine oxygen forming hydrogen bonds with Val211 and Ser212 and 5 
the pyrimidine oxygen interacting with Lys97. The 2-fluoro-4-iodoaniline moiety functions as a 6 
recognition motif for the hydrophobic pocket of the MEK allosteric site. The hydroxyl groups of the 7 
terminal dihydroxypropyl chain forms hydrogen bonds with both the ATP phosphate and Lys97 [87] 8 
(Figure 12C).  A combination strategy of B-Raf inhibitor dabrafenib with MEK inhibitor trametinib, 9 
approved for the treatment of mutant V600E/K metastatic melanoma by FDA in early 2014, has 10 
been used to overcome drug resistance that occurs within about half a year after applying B-Raf 11 
inhibitors [88, 89].  12 
Serine/threonine kinases Akt and mTOR of the PI3K/Akt/mTOR pathway are also promising 13 
targets [90]. Although no small molecule kinase inhibitors has been approved for either Akt or 14 
mTOR, a pipeline of candidates are currently undergoing various clinical trials in different phases 15 
[91]. For mTOR inhibitors, three natural-product-based macrolides, sirolimus, temsirolimus, and 16 
everolimus, were approved for clinical use in 1999, 2007, and 2009, respectively [90]. 17 
Cyclin-dependent kinases (CDKs) represent another group of serine/threonine kinases that have 18 
been studied as targets for therapeutic intervention in various types of cancers and other 19 
proliferative diseases [92]. Intensive efforts have been made in the past two decades to discover 20 
inhibitors with varied selectivity against the eleven isoforms of CDKs, resulting in the emergence of 21 
approximately twenty CDK inhibitors currently in various clinical trials [93]. Eventually, the first 22 
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CDK inhibitor palbociclib (Ibrane®, Pfizer) was approved in February 2015 inhibitor for the 1 
treatment of breast cancer.  2 
Palbociclib is a selective CDK4 and CDK6 inhibitor (Figure 13A). Due to conformational difference 3 
in the hinge region of CDKs, the selectivity profiles of CDK inhibitors are closely connected with 4 
their binding orientations [94]. Co-crystal structure of palbociclib with CDK6 showed a tight 5 
binding mode, in which hydrogen bonds are formed between the hinge residue Val101 and the 6 
aminopyrimidine moiety and between the DFG residue Asp163 and the 6-acetyl group. The 5-7 
methyl and 6-acetyl groups fully occupy a hydrophobic pocket in the back of the ATP binding site. 8 
The piperazinylpyridinylamino substituent at the 2-position of the pyrido[2,3-d]pyrimidinone core 9 
binds into a specificity pocket facing to the solvent front (Figure 13B, 13C). Overall, palbociclib 10 
binds tightly into CDK6 and adopts a comparatively rigid orientation in comparison with other pan-11 
CDK inhibitor due to the above-mentioned binding features [94].  12 
Approved lipid kinase inhibitor 13 
Lipid kinases, such as phosphoinositide 3 kinases (PI3Ks), were discovered as early as the 1980s 14 
[95]. It has been convincingly established that activation and mutation of PI3Ks and other key 15 
components of this signaling pathway play key roles in various stages of tumor development [96]. 16 
Considerable efforts from both academia and industry have been involved in the development of 17 
small molecule lipid kinases since 1980s, but the clinical success of these inhibitors has been 18 
minimal until the approval of the first lipid kinase inhibitor, idelalisib (Zydelig®, Gilead Sciences), 19 
for CLL in combination with monoclonal antibody rituximab in July 2014 [97]. The approval of 20 
idelalisib, together with the BTK inhibitor ibrutinib, provides encouraging transformation in the 21 
treatment of CLL [98]. 22 
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Idelalisib is a PI3Kδ inhibitor [99] (Figure 14A). The crystal complex of PI3Kδ with idelalisib 1 
revealed a type II binding that is similar to that of another selective PI3Kδ inhibitor PIK39 [100]. 2 
Idelalisib adopts a propeller-shaped conformation with the DFG motif posing in an “out” 3 
conformation [101]. The 5-fluoroquinazolinone moiety squeezes into an induced hydrophobic 4 
specificity pocket. The ethyl group binds in a hydrophobic pocket and the phenyl group extends 5 
into a hydrophobic region that is close to the solvent front. The hinge hydrogen bond, which is a 6 
highly conserved feature for PI3K inhibition [102], is formed between Val828 and the purine 7 
moiety that occupies the adenine pocket [101] (Figure 14B, 14C). Except for being approved for 8 
CLL, idelalisib has also been granted accelerated approval for relapsed follicular B-cell non-Hodgkin 9 
lymphoma and relapsed small lymphocytic lymphoma [103, 104]. 10 
More than twenty other PI3K inhibitors, including single-isoform inhibitors, such as PI3Kα 11 
inhibitor buparlisib (phase III, Novartis), selective-isoform inhibitors, dual inhibitors of PI3K and 12 
mTOR, and pan class-I PI3K inhibitors, are in development for cancers and inflammatory diseases 13 
[102]. However, the clinical data accumulated so far suggest that PI3K inhibitors have limited 14 
single-agent activity [105], possibly due to negative feedback inhibition and the resulting 15 
reactivation of downstream receptor signaling [106, 107]. Thus, rational combination strategies 16 
using monoclonal antibodies, tyrosine kinase inhibitors, and serine/threonine kinase inhibitors are 17 
needed to assist the clinical usage of PI3K inhibitors. 18 
Limitations and challenges 19 
Kinase-based drug discovery has achieved dramatic progress in the past fifteen years. Although 20 
kinase inhibition stands for a young therapeutic strategy in comparison with other traditional 21 
tactics targeting G-protein-coupled receptors (GPCRs), membrane channels and transporters, 22 
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protease, etc., an analysis of FDA-approved cancer drugs since 1980s reveals that kinases have 1 
already taken over from G-protein-coupled receptor (GPCR) as the most sought-after cellular 2 
targets for cancer treatment [108]. Our analysis of all FDA-approved molecule kinase inhibitors 3 
with a focus on binding mechanism and structural features reveals some general conclusions that 4 
form the current landscape of developing kinase inhibitors and reflects a number of significant 5 
challenges in spite of achieved advances. 6 
First, only a small subset of the human kinome has been studied. Most kinase inhibition efforts 7 
are limited to a select group of kinases that belong to the tyrosine kinase (TK) group, although 8 
promising results are emerging for inhibition of kinases in groups of tyrosine-kinase like (TKL), 9 
containing CDK, MAPK, GSK3 and CLK kinases (CMGC), containing PKA, PKG and PKC kinases (AGC), 10 
and containing the calcium/calmodulin-dependent protein kinases (CAMK) in recent years. This 11 
imbalance is clearly illustrated by the fact that inhibitors of three groups of tyrosine kinases, BCR-12 
Abl, ErbBs, VEGFRs, account for eighteen of the twenty-seven approved protein kinase inhibitors. 13 
Second, in contrast with protein kinase inhibitors, only one lipid kinase inhibitor is currently on 14 
the market. Even though lipid kinase inhibitors were reported as early as 1990s and a variety of 15 
clinical and pre-clinical lipid kinase inhibitors have been published [102], few have showed 16 
sufficient activity used in single-agent trials. 17 
    Third, despite the fact that kinases signaling cascade regulates diverse cellular activities related 18 
to inflammatory indications, CNS disorders, cardiovascular disease, diabetes, and others, in 19 
addition to cancer, most currently available inhibitors, including 26 out of the 28 approved kinase 20 
inhibitors, are developed mainly for cancer treatment.  21 
    Fourth, many of the current kinase inhibitors were designed based on previously approved 22 
compounds, as shown by the high structural similarity among approved ErbB inhibitors, e.g., five 23 
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ErbB inhibitors share the same 4-(arylamino)quinazoline core with different 6- and/or 7-1 
substituents. Consequently, only a small subset of chemotypes are being investigated, which is 2 
clearly reflected by the limited number of moieties that are being incorporated in the approved 3 
molecules. 4 
Fifth, most inhibitors function as reversible inhibitors binding in the ATP binding pocket and due 5 
to the high sequence similarity around the ATP binding pockets of kinases, it has been a daunting 6 
task to develop kinase inhibitors with potent inhibition against desirable targets and minimal 7 
interactions with off-targets. 8 
Sixth, closely connected with the previous point, a large number of inhibitors interact with more 9 
than one target. In contrast, few absolute-selective inhibitors, which might be evaluated as dual or 10 
multiple target inhibitors if a more comprehensive screening assay was used [109], have been 11 
identified so far.  12 
Future directions 13 
    Based on the current trends discussed above, some challenging questions that might serve as 14 
directions for future development of small molecule kinase inhibitors and push the boundary of 15 
the research in this field need to be addressed appropriately. 16 
    First, the fact that current kinase inhibitors focus only on a small subset of the human kinome 17 
indicates that many kinases are neglected. Thus, there is a need to develop tools and selective 18 
probes to uncover the functions of these unknown kinases [110], which might serve as new 19 
targets for small molecule inhibitors. It is encouraging to see the approval of a first inhibitor 20 
targeting certain kinases in the past three years, like trametinib as the first approved MEK inhibitor 21 
in 2013, ibrutinib as the first approved BTK inhibitor in 2013, and palbociclib as the first approved 22 
CDK inhibitor in 2015. 23 
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    Second, although significant efforts have been devoted to the development of lipid kinase 1 
inhibitors, the progress achieved is not as obvious as for protein kinase inhibitors. The approval of 2 
the first and only lipid kinase inhibitor idelalisib in 2014 added support to the strategy of using 3 
lipid kinase inhibitors as anticancer agents, especially in combination with other cancer treatment 4 
agents and methods. Considering the pivotal roles of lipids kinases, such as PI3Ks, in cellular 5 
cascade, it is reasonable to expect research on small molecule lipid kinase inhibitors for indications 6 
including not only cancer but also inflammation, to be a promising direction in this field. 7 
Third, except being utilized in the prevalent theme for cancer treatment, kinase inhibitors have 8 
great potential in the treatment of nonlethal chronic diseases, such as cardiovascular and CNS 9 
disorders. The successful approval of tofacitinib established the concept for the treatment of 10 
arthritis. Even for cancer treatment, more knowledge needs to be gained to further understand 11 
the multifaceted cancer biology. 12 
    Fourth, more pharmacophores need to be explored to diversify the scaffolds of kinase inhibitors. 13 
Most currently approved kinase inhibitors are discovered based on hits from high-throughput 14 
screening (HTS), while HTS is becoming increasingly less effective since most useful scaffolds have 15 
already been retrieved from available compound libraries. So there is an urgent need to diversify 16 
the molecules in compound library for screening. Natural products, which usually contain 17 
pharmacophores and scaffolds that are different from most synthetic kinase inhibitors, could be a 18 
useful source to inspire the construction of libraries with expanded structural diversity. 19 
Fifth, despite the fact that most approved kinase inhibitors are type I and II reversible inhibitors, 20 
the success of afatinib and ibrutinib stand as strong stimulators to rekindle the idea of targeting 21 
kinases with irreversible inhibitors. On the other hand, type III and IV inhibitors might show 22 
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different efficacy and selectivity in comparison with type I and II inhibitors. In a word, novel 1 
mechanism of action needs to be explored. 2 
Sixth, the selectivity issue of kinase inhibitors has always been a controversial area. Early 3 
promiscuous inhibitors, e.g. staurosporine, and later pan-selective inhibitors have functioned as 4 
useful tools in oncology. Highly selective kinase inhibitors were actively sought after until the 5 
recent theory that inhibitors with favorable selectivity or multi-target selectivity might be more 6 
suitable for cancer treatment becoming more and more widely accepted. It has become clear that 7 
kinase inhibitors do not have to be absolute-selective, a favorable selectivity profile is needed to 8 
balance efficacy and toxicity.  9 
Concluding remarks 10 
Groundbreaking understanding of cellular signaling cascades at the molecular level has led to 11 
major advances in kinase research over the past decades. The dramatic progress in applying the 12 
strategy of targeted kinase inhibition in the past fifteen years has been highlighted by the 13 
successful approval of no less than twenty-eight small molecule kinase inhibitors. An analysis 14 
based on co-crystal structures of all approved inhibitors with a focus on binding mechanism and 15 
structural features is presented herein to provide an updated overview of the achievements and 16 
shape current limitations and challenges in this rapidly evolving field. Future directions that may 17 
lead to the discovery of small molecule kinase inhibitors with novel function mechanisms, new 18 
therapeutic indications, distinct structures, and different selectivity and pharmacological profiles 19 
are also proposed. Although the current task of developing small molecule kinase inhibitors is 20 
highly interdisciplinary, the ultimate answer to the question of which type of kinase inhibitor is 21 
most useful will have to come from the accumulated clinical data of the approved molecules 22 
discussed in this review.  23 
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Figure legend 1 
[Figure 1] 2 
Figure 1. Kinase structure and different types of reversible small molecule kinase inhibitors. (A) Co-3 
crystal structure of PDK1 with ATP (adenine and ribose in green backbone, phosphate groups in 4 
orange) with the enlarged area showing the structural elements around the ATP binding site. 5 
Hydrogen bonds in red dotted lines, hinge region and hinge residues in green backbone, P-loop 6 
and P-loop residue in brown orange backbone, the aspartate residue of the DFG motif and the 7 
activation loop in white backbone (PDB ID: 4RRV, 1.41 Å). (B) Four types of reversible binding 8 
modes: type I inhibitors bind to the active conformation of kinase with the aspartate residue 9 
(white backbone) of the DFG motif pointing into the ATP-binding pocket; type II inhibitors bind 10 
and stabilize the inactive conformation of kinase with the flipped aspartate residue facing outward 11 
of the binding pocket; type III inhibitors occupy an allosteric pocket that is adjacent to the ATP 12 
binding pocket but does not overlap with it; type IV inhibitors bind to an allosteric pocket remote 13 
from the ATP binding pocket.  14 
[Figure 2] 15 
Figure 2. FDA approved small molecule kinase inhibitors (as of March 2015).  16 
[Figure 3] 17 
Figure 3. Type II inhibitors of BCR-Abl. (A) Chemical structure of imatinib and its depicted binding 18 
mode with BCR-Abl. (B) Imatinib co-crystal structure (PDB ID: 1IEP, 2.10 Å). (C) Chemical structure 19 
of nilotinib and its depicted binding mode with BCR-Abl. (D) Nilotinib co-crystal structure (PDB ID: 20 
3CS9, 2.21 Å). (E) Chemical structure of ponatinib and its depicted binding mode with BCR-Abl. (F) 21 
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Ponatinib co-crystal structure with wild-type BCR-Abl (PDB ID: 3OXZ, 2.20 Å).  Small molecule 1 
inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted lines, and 2 
residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and 3 
π-interactions formed between certain aromatic rings of these molecules and residues including 4 
Phe and Tyr are not illustrated in these ribbon-show figures. Co-crystal structures of ponatinib 5 
(PDB ID: 3IK3, 1.9 Å) and its analogue (PDB ID: 3OY3, 1.95 Å) with mutant T315I (shown in yellow 6 
backbone in F) BCR-Abl have also been released. 7 
[Figure 4] 8 
Figure 4. Inhibitors binding with active BCR-Abl. (A) Chemical structure of dasatinib and its 9 
depicted binding mode with BCR-Abl. (B) dasatinib co-crystal structure (PDB ID: 2GQG, 2.40 Å). (C) 10 
Surface show of the dasatinib-Abl co-crystal structure (PDB ID: 2GQG, 2.40 Å).  (D) Chemical 11 
structure of bosutinib and its depicted binding mode with BCR-Abl. (E) Bosutinib co-crystal 12 
structure (PDB ID: 3UE4, 2.42 Å).  (F) Surface show of the bosutinib-Abl co-crystal structure (PDB ID: 13 
2GQG, 2.40 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are 14 
indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are 15 
shown in green backbone, the gate-keeper residue is shown in yellow backbone, and residues of 16 
the DFG motif are shown in white backbones. 17 
[Figure 5] 18 
Figure 5. JAK inhibitors. (A) Chemical structure of ruxolitinib. (B) Chemical structure of tofacitinib 19 
and its depicted binding mode with JAK2/3. (C) Tofacitinib co-crystal structure with JAK3 (PDB ID: 20 
3LXK 2.0 Å). (D) Tofacitinib co-crystal structure with JAK2 (PDB ID: 3FUP 2.4 Å).  Tofacitinib shown 21 
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in magenta backbone, hydrogen bonds are indicated by red dotted lines, and residues that 1 
interact with tofacitinib through hydrogen bonds are shown in green backbone. 2 
[Figure 6] 3 
Figure 6. Small molecule kinase inhibitors against ErbBs. (A) Chemical structure of gefitinib and its 4 
depicted binding mode with EGFR. (B) Gefitinib co-crystal structure with wild type EGFR (PDB ID: 5 
2ITY, 3.42 Å). (C) Gefitinib co-crystal structure with mutant L858R+T790M+V948R EGFR (PDB ID: 6 
4I22, 1.71 Å). (D) Chemical structure of erlotinib and its depicted binding mode with EGFR. (E) 7 
Erlotinib co-crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). (F) Surface show of erlotinib co-8 
crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). (G) Chemical structure of lapatinib and its 9 
depicted binding mode with EGFR. (H) Lapatinib co-crystal structure with EGFR (PDB ID: 1XKK, 2.40 10 
Å).  (I) Lapatinib-ErbB4 complex, the methylsulfonylethanylaminomethylfuranyl moiety is not 11 
shown in this crystal structure (PDB ID: 3BBT, 2.80 Å). (J) Chemical structure of vandetanib and its 12 
depicted binding mode with RET. (K) Vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50 13 
Å). (L) Surface show of vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50 Å). Small 14 
molecule inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted 15 
lines, residues that interact with inhibitors through hydrogen bonds are shown in green backbone, 16 
residue 858 and residue 790 in the gefitinib-EGFR complex are shown in yellow backbone, and 17 
residues of the DFG-motif are shown in white backbone. 18 
[Figure 7] 19 
Figure 7. Small molecule kinase inhibitors binding to VEGFR. (A) Chemical structure of sorafenib 20 
and its depicted binding mode with VEGFR2. (B) Sorafenib co-crystal structure with VEGFR2 (PDB 21 
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ID: 4ASD, 2.03 Å). (C) Chemical structure of sunitinib and its depicted binding mode with VEGFR2. 1 
(D) Sunitinib co-crystal structure with VEGFR2 (PDB ID: 4AGD, 2.81 Å). (E) Chemical structure of 2 
axitinib and its depicted binding mode with VEGFR2. (F) Axitinib co-crystal structure with VEGFR2 3 
(PDB ID: 4AG8, 1.95 Å).  (G) Chemical structure of nintedanib and its depicted binding mode with 4 
VEGFR2. (H) Nintedanib co-crystal structure with VEGFR2 (PDB ID: 3C7Q, 2.10 Å).  (I) Chemical 5 
structure of regorafenib. (J) Chemical structure of pazopanib and its proposed binding mode with 6 
VEGFR2 based on crystal structure of PDB ID: 3CJG (2.25 Å). (K) Chemical structure of lenvatinib 7 
and its depicted binding mode with VEGFR2. Small molecule inhibitors are shown in magenta 8 
backbone, hydrogen bonds are indicated by red dotted lines, and residues that interact with 9 
inhibitors through hydrogen bonds are shown in green backbone. 10 
[Figure 8] 11 
Figure 8. Small molecule kinase inhibitors binding to ALK. (A) Chemical structure of crizotinib and 12 
its depicted binding mode with ALK. (B), (C) Crizotinib co-crystal structure with ALK (PDB ID: 2XP2, 13 
1.9 Å). (D) Chemical structure of ceritinib and its depicted binding mode with ALK. (E), (F) Ceritinib 14 
co-crystal structure with ALK (PDB ID: 4MKC, 2.01 Å).  Small molecule inhibitors are shown in 15 
magenta backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with 16 
inhibitors through hydrogen bonds are shown in green backbone, and residues of the DGF motif 17 
are shown in white backbone. 18 
[Figure 9] 19 
Figure 9. Small molecule kinase inhibitors binding to MET. (A) Depicted binding mode of crizotinib 20 
with MET. (B), (C) Crizotinib co-crystal structure with MEK (PDB ID: 2WGJ, 2.0 Å). (D) Chemical 21 
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structure of cabozantinib. (E) Chemical structure of compound DWF (name derived from PDB 1 
ligand identifier code) and its depicted binding mode with MET. (F, G) Cabozantinib co-crystal 2 
structure with MET (PDB ID: 4MXC, 1.63 Å).  Small molecule inhibitors are shown in magenta 3 
backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with inhibitors 4 
through hydrogen bonds are shown in green backbone, and the Asp residue of the DGF motif is 5 
shown in white backbone. 6 
[Figure 10] 7 
Figure 10. Binding mode of irreversible small molecule kinase inhibitors.  (A) Chemical structure of 8 
afatinib and its depicted binding mode with EGFR. (B) Afatinib co-crystal structure with wildtype 9 
EGFR (PDB ID: 4G5J, 2.80 Å). (C) Afatinib co-crystal structure with mutant T790M EGFR (PDB ID: 10 
4G5P, 3.17 Å). (D) Chemical structure of ibrutinib and its proposed binding mode with BTK. (E) 11 
Chemical structure of compound B43 and its depicted binding mode with BTK. (F) B43 co-crystal 12 
structure with BTK (PDB ID: 3GEN, 1.60 Å). Wild type and mutant residue790 of EGFR is shown in 13 
yellow backbone, small molecule inhibitors are shown in magenta backbone, hydrogen bonds are 14 
indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are 15 
shown in green backbone, covalent bonds are indicated by purple solid lines, and the cysteine 16 
residue contributing to the formation of a covalent bond is shown in purple backbone. 17 
[Figure 11] 18 
Figure 11. Structures of approved small molecule kinase inhibitors binding to serine/threonine 19 
kinase B-Raf. (A) Chemical structure of vermurafenib and its depicted binding mode with mutant 20 
V600E B-Raf kinase. (B) Vemurafenib co-crystal structure with V600E B-Raf (PDB ID: 3OG7, 2.45 Å). 21 
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(C) Surface show of the vemurafenib-V600E B-Raf complex with the residues of the DFG motif 1 
highlighted in white backbones (PDB ID: 3OG7, 2.45 Å). (D) Chemical structure of dabrafenib. (E) 2 
Chemical structure of the dabrafenib derivative compound 20 and its depicted binding mode with 3 
mutant V600E B-Raf. (F) Compound 20 co-crystal structure with V600E B-Raf (PDB ID: 4CQE, 2.30 4 
Å). (G) Chemical structure of sorafenib and its depicted binding mode with wild type B-Raf. (H) 5 
Sorafenib co-crystal structure with wild type B-Raf (PDB ID: 1UWH, 2.95 Å). (I) Sorafenib co-crystal 6 
structure with mutant V599E B-Raf, mutated residue Glu599 is shown in brown backbone (PDB ID: 7 
1UWJ, 3.5 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are 8 
indicated by red dotted lines, and residues that interact with inhibitors through hydrogen bonds 9 
are shown in green backbone.  10 
[Figure 12] 11 
Figure 12. MEK kinase inhibitor binding mode. (A) Chemical structure of trametinib. (B) Chemical 12 
structure of Tak-733 and its depicted binding mode with MEK1. (C) Tak-733 co-crystal structure 13 
with MEK1 (PDB ID: 3PP1, 2.70 Å).  ATP is shown in cyan backbone, Tak-733 in magenta backbone, 14 
hydrogen bonds are indicated by red dotted lines, and residues that interact with ATP and Tak-733 15 
through hydrogen bonds are shown in green backbone. 16 
[Figure 13] 17 
Figure 13. CDK inhibitor palbociclib. (A) Chemical structure of palbociclib and its depicted binding 18 
mode with CDK6. (B), (C) Palbociclib co-crystal structure with CDK6 (PDB ID: 2EUF, 3.0 Å). 19 
Palbociclib is shown in magenta backbone, hydrogen bonds are indicated by red dotted lines, 20 
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residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and 1 
residues of the DFG motif are shown in white backbones.  2 
[Figure 14] 3 
Figure 14. PI3Kδ inhibitor idelalisib. (A) Chemical structure of idelalisib and its depicted binding 4 
mode with PI3Kδ. (B), (C) Idelalisib co-crystal structure with PI3Kδ (PDB ID: 4XE0, 2.43 Å). Idelalisib 5 
is shown in magenta backbone, hydrogen bond is indicated by a red dotted line, and residues of 6 
the DFG motif are shown in white backbones.  7 
